Effect of aliskiren on cardiovascular outcomes in patients with prehypertension: A meta-analysis of randomized controlled trials

Drug Design, Development and Therapy

Volumn 9, Issue , 2015, Pages 1963-1971

  Zhang, Jing Tao ^a   Chen, Ke Ping ^a   Guan, Ting ^a   Zhang, Shu ^a  

^a FUWAI HOSPITAL   (China)

Author keywords

Aliskiren; Cardiovascular disease; Meta analysis; Stroke; Systematic review

Indexed keywords

ALISKIREN; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; LOSARTAN; MINERALOCORTICOID ANTAGONIST; PLACEBO; AMIDE; FUMARIC ACID DERIVATIVE;

CARDIOVASCULAR DISEASE; CEREBROVASCULAR ACCIDENT; HEART DEATH; HEART FAILURE; HEART INFARCTION; HUMAN; META ANALYSIS; MICROALBUMINURIA; MORTALITY; PREHYPERTENSION; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK FACTOR; SYSTEMATIC REVIEW; TREATMENT OUTCOME; CARDIOVASCULAR DISEASES;

AMIDES; CARDIOVASCULAR DISEASES; FUMARATES; HUMANS; PREHYPERTENSION; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TREATMENT OUTCOME;

EID: 84929154751     PISSN: None     EISSN: 11778881     Source Type: Journal    
DOI: 10.2147/DDDT.S75111     Document Type: Review

References (28)

1. Lewington S, Clarke R, Qizilbash N, Peto R, Collins R. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet. 2002;360(9349):1903–1913.
2. Rosamond W, Flegal K, Furie K, et al. Heart disease and stroke statistics-2008 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation. 2008;117(4):e25–e146.
3. Persson F, Lewis JB, Lewis EJ, Rossing P, Hollenberg NK, Hans-Henrik P. Impact of aliskiren treatment on urinary aldosterone levels in patients with type 2 diabetes and nephropathy: an AVOID substudy. J Renin Angiotensin Aldosterone Syst. 2012;13(1):118–121.
4. Jeunemaitre X, Menard J, Nussberger J, Guyene TT, Brunner HR, Corvol P. Plasma angiotensins, renin, and blood pressure during acute renin inhibition by CGP 38 560A in hypertensive patients. Am J Hypertens. 1989;2(11 Pt 1):819–827.
5. Azizi M, Menard J. Combined blockade of the renin-angiotensin system with angiotensin-converting enzyme inhibitors and angiotensin II type 1 receptor antagonists. Circulation. 2004;109(21):2492–2499.
6. Jamerson KA, Nwose O, Jean-Louis L, Schofield L, Purkayastha D, Baron M. Initial angiotensin-converting enzyme inhibitor/calcium channel blocker combination therapy achieves superior blood pressure control compared with calcium channel blocker monotherapy in patients with stage 2 hypertension. Am J Hypertens. 2004;17(6):495–501.
7. Poldermans D, Glazes R, Kargiannis S, et al. Tolerability and blood pressure-lowering efficacy of the combination of amlodipine plus valsartan compared with lisinopril plus hydrochlorothiazide in adult patients with stage 2 hypertension. Clin Ther. 2007;29(2):279–289.
8. Gradman AH, Schmieder RE, Lins RL, Nussberger J, Chiang Y, Bedigian MP. Aliskiren, a novel orally effective renin inhibitor, provides dose-dependent antihypertensive efficacy and placebo-like tolerability in hypertensive patients. Circulation. 2005;111(8):1012–1018.
9. Parving HH, Brenner BM, McMurray JJ, et al. Cardiorenal End Points in a Trial of Aliskiren for Type 2 Diabetes. N Engl J Med. 2012;367(23): 2204–2213.
10. Flack JM, Yadao AM, Purkayastha D, Samuel R, White WB. Comparison of the effects of aliskiren/valsartan in combination versus valsartan alone in patients with Stage 2 hypertension. J Am Soc Hypertens. 2012; 6(2):142–151.
11. Gheorghiade M, Böhm M, Greene SJ, et al. Effect of Aliskiren on Postdischarge Mortality and Heart Failure Readmissions Among Patients Hospitalized for Heart Failure The ASTRONAUT Randomized Trial. JAMA. 2013;309(11):1125–1135.
12. Makani H, Bangalore S, Desouza KA, Shan A, Messerli FH. Efficacy and safety of dual blockade of the renin-angiotensin system: meta-analysis of randomised trials. BMJ. 2013;346:f360.
13. Moher D, Liberati A, Tetzlaff J, Altman DG; PRISMA Group. Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. PLoS Med. 2009;6(7):e1000097.
14. Jadad AR, Moore RA, Carroll D, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials. 1996;17(1):1–12.
15. Kones R. Primary prevention of coronary heart disease: integration of new data, evolving views, revised goals, and role of rosuvastatin in management. A comprehensive study. Drug Des Devel Ther. 2011;5:325–380.
16. Ades AE, Lu G, Higgins JP. The interpretation of random-effects meta-analysis in decision models. Med Decis Making. 2005;25(6):646–654.
17. Deeks JJ, Higgins JP, Altman DG. Analyzing data and undertaking meta-analyses. In: Higgins J, Green S, editors. Cochrane Handbook for Systematic Reviews of Interventions 5.0.1. Oxford, UK: The Cochrane Collaboration; 2008.
18. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003;327(7414):557–560.
19. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315(7109):629–634.
20. Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics. 1994;50(4):1088–1101.
21. Parving HH, Persson F, Lewis JB, Lewis EJ, Hollenberg NK; AVOID study investigators. Aliskiren Combined with Losartan in Type 2 Diabetes and Nephropathy. N Engl J Med. 2008;358(23):2433–2446.
22. Scirica BM, Morrow DA, Bode C, et al. Patients with acute coronary syndromes and elevated levels of natriuretic peptides: the results of the AVANT GARDE-TIMI 43 Trial. Eur Heart J. 2010;31(16):993–2005.
23. Solomon SD, Shin SH, Shah A, et al. Effect of the direct renin inhibitor aliskiren on left ventricular remodelling following myocardial infarction with systolic dysfunction. Eur Heart J. 2011;32(10):1227–1234.
24. Nicholls SJ, Bakris GL, Kastelein JJ, et al. Effect of Aliskiren on Progression of Coronary Disease in Patients With Prehypertension The AQUARIUS Randomized Clinical Trial. JAMA. 2013;310(11):1135–1144.
25. Pool JL, Schmieder RE, Azizi M, et al. Aliskiren, an Orally Effective Renin Inhibitor, Provides Antihypertensive Efficacy Alone and in Combination With Valsartan. Am J Hypertens. 2007;20(1):11–20.
26. Gao D, Ning N, Niu X, Wei J, Sun P, Hao G. Aliskiren vs. angiotensin receptor blockers in hypertension: meta-analysis of randomized controlled trials. Am J Hypertens. 2011;24(5):613–621.
27. Harel Z, Gilbert C, Wald R, et al. The effect of combination treatment with_aliskiren_and blockers of the renin-angiotensin system on hyperkalaemia and acute kidney injury: systematic review and- meta-analysis. BMJ. 2012;344(1):e42.
28. Nathan SD, King CS. Treatment of pulmonary hypertension in idiopathic pulmonary fibrosis: shortfall in efficacy or trial design? Drug Des Devel Ther. 2014;8:875–885.